ISCT Webinar: Challenges and Optimization of Apheresis Collection for Immunotherapy in Non-Mobilized Patients and Donors
Organized by the ISCT Immunotherapy Committee
Sponsored by Terumo BCT
Wednesday April 13, 2016 at 12:00 PDT, 15:00 EDT, 21:00 CEST
Chair: Patrick Hanley, PhD, Children's National Medical Center, USA
Richard Smith, Global Senior Scientist, Therapeutic Systems, Terumo BCT, Inc., USA
Andrew Fesnak, MD, Penn Medicine, University of Pennsylvania Health System, Division of Transfusion Medicine and Therapeutic Pathology, Department, USA
About the webinar:
Increasingly, cell-based immunotherapy has come to rely on the acquisition of large numbers of peripheral blood mononuclear cells collected by leukapheresis. Both quality and quantity of the apheresis product, and variance between products, has a direct bearing on the ability to reliably manufacture a consistent therapeutic product in a timely and cost-effective manner. Better understanding of the constraints imposed by the number of available target cells in the patient, and better ability to predict outcome, may also help avoid costly failures during downstream processing.
Sophisticated apheresis equipment have been designed that enhance usability and use combinations of hardware and software controls to optimize collections, and improve product uniformity across a wide range of settings. Considerable expertise and publications have accumulated in leukapheresis collections directed towards isolation of CD34+ cells from patients and donors after mobilization with growth factors alone or after chemotherapy. Collection in a non-mobilized setting, and more specifically in patients, raises unique challenges. In this context, there needs to be detailed and specific requirements set by the prescriber that describe precise target cell yields, product volume and purity. These goals may require more specific optimization before and during apheresis. Total blood volume to be processed may require modification to acquire adequate target cell yield and it may be necessary to strike a balance between the final product yield and purity. Finally, and most importantly, the impact of leukapheresis on the patient has to be considered. The ability to access and process an adequate volume of blood in an acceptable time with minimal side effects or loss of platelets and other non-target cells is critical.
The purpose of this webinar is to describe the underlying principles of apheresis, review specific challenges in non-mobilized apheresis and areas where performance optimization may best help meet manufacturing requirements.
Understand the principles of leukapheresis and operator-controlled variables that may be modified to optimize products
Review challenges encountered in non-mobilized leukapheresis and strategies that may be developed to address these
Understand how leukapheresis optimization may influence product quality and quantity
Understand the basis of yield prediction based on pre-apheresis cell counts